Entellus Medical (ENTL) Receiving Somewhat Favorable Media Coverage, Analysis Shows

News stories about Entellus Medical (NASDAQ:ENTL) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Entellus Medical earned a news impact score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical technology company an impact score of 46.2115296533271 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

NASDAQ ENTL traded down $0.01 on Thursday, reaching $24.00. 43,800 shares of the stock traded hands, compared to its average volume of 178,331. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical has a 12 month low of $11.47 and a 12 month high of $25.58.

How to Become a New Pot Stock Millionaire

A number of equities research analysts have weighed in on ENTL shares. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. BidaskClub raised Entellus Medical from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $20.33.

COPYRIGHT VIOLATION WARNING: This story was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://ledgergazette.com/2018/04/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-entellus-medical-entl-share-price.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply